Document:

CONFIDENTIAL DOCUMENT

                                  17 July 2000

                    PROFESSIONAL SERVICES and CONFIDENTIALITY
                                AGREEMENT between
                                   Lexon, Inc.
                                        &
                          DIAGNOSTIC ONCOLOGY CRO, Inc.

                                     PARTIES

The parties to this  Professional  Services and  Confidentiality  Agreement  are
Lexon,  Inc. and its affiliates,  subsidiaries and the like ("LEXON") located in
Tulsa,  Oklahoma,  and  DIAGNOSTIC  ONCOLOGY  CRO,  Inc.  ("DOCRO"),  located in
Seymour, Connecticut.

                                    PURPOSES

LEXON is engaged in the business of developing medical  diagnostic  products for
distribution  to the  biotechnology,  healthcare,  medical  diagnostic,  medical
device, and therapeutic  industries,  in particular,  in vitro diagnostic assays
for  determining  the amount of ebaf tumor marker in the tissues,  blood,  other
fluids, and other specimen matrices of mammals.

DOCRO is engaged in providing technology assessment, technology development, and
laboratory  and  clinical  trial  services  to  medical  device  developers,  in
particular,  providing technology assessment and technology development services
related to the development and  commercialization  of in vitro diagnostic assays
for  determining  the amount of tumor markers or other  analytes in the tissues,
blood, other fluids, and other specimen matrices of mammals.

LEXON wishes to engage DOCRO to conduct a technology  assessment and development
program for LEXON's ebaf tumor marker technology. This program requires DOCRO to
assess the current  technical  and clinical  performance  of the  existing  ebaf
reagents as provided by Dr. S.Tabibzadeh, North Shore University Hospital, North
Shore,  New York, then for DOCRO to develop  purified ebaf antigens  (native and
recombinant  protein  and  various  peptides,  for all four known  forms of ebaf
protein  expressed in human tissue (precursor ebaf protein having an approximate
molecular weight (including  native  glycosylation) of 42 kDa, and three clipped
forms of this precursor having  approximate  molecular weights (including native
glycosylation)  of 34 kDa,  26 kDa,  and 14 kDa) and then to raise a variety  of
monoclonal  antibodies  and polyclonal  antibodies to these various  antigens to
determine  if any ebaf  protein is  overexpressed  in the tissue,  blood,  other
fluids, and other specimen matrices from humans diagnosed with colorectal cancer

<PAGE>

when compared to similar  specimens from apparently  healthy,  normal humans and
from  a  variety  of  humans   diagnosed  with  other   malignant   diseases  or
non-malignant diseases. Further, if an ebaf protein is determined by DOCRO to be
overexpressed  in  malignant  disease  and  not  in  non-malignant   disease  or
apparently  healthy  normals and LEXON  agrees,  DOCRO  shall  develop an enzyme
immunoassay  for such ebaf  protein to confirm the results in the blood or other
fluid specimen  matrix of a  statistically  significant  number (maximum of 400)
patients.

In consideration of the mutual promises specified below, DOCRO offers to provide
technology assessment and technology development  professional services to LEXON
in  accordance  with the terms and  conditions  of this  Agreement,  which LEXON
accepts.

                                   DEFINITIONS

"Confidential & Proprietary  Information" shall include any information owned by
any party, as well as information developed by DOCRO in connection with services
performed  under this Agreement which shall be considered  LEXON's  confidential
information,  whether or not such information is in oral, written or other form,
or was  denominated or specifically  identified as confidential  when disclosed,
observed or  developed.  Such  information  may  include,  but is not limited to
commercial or  technological  plans,  customer lists,  discoveries,  inventions,
know-how,  processes,  software,  suppliers,  trade  secrets,  as  well  as  any
analytical chemical or biological specimens or prototypes.

"DOCRO" shall mean the entity  identified in the PARTIES section,  including any
entities affiliated with DOCRO,  including but not limited to DOCRO's employees,
agents, officers or principals, and, its contractors.

"LEXON" shall mean the entity  identified in the PARTIES section,  including any
entities affiliated with LEXON (or any purchaser of substantially all of LEXON's
assets),  including but not limited to LEXON's  employees,  agents,  officers or
principals, and, its contractors.

"PRODUCTS"  shall mean LEXON's ebaf  technology  used for the assessment  and/or
development of an in vitro  diagnostic assay to determine if any ebaf protein is
overexpressed in the tissue,  blood,  other fluids,  and other specimen matrices
from humans diagnosed with colorectal  cancer when compared to similar specimens
from apparently  healthy,  normal humans and from a variety of humans  diagnosed
with other malignant diseases or non-malignant diseases, including any native or
recombinant  ebaf protein or peptide antigen in any form, and antibody raised to
any native or recombinant ebaf protein or peptide antigen.

                                   --2 of 14--

<PAGE>

                              TERMS AND CONDITIONS

1.0   Services to be Provided by DOCRO

1.1. Technology  Assessment - DOCRO shall assess for LEXON the current technical
and clinical  performance of the existing ebaf reagents as provided by LEXON and
the inventor,  Dr. S.Tabibzadeh,  North Shore University Hospital,  North Shore,
New York.

1.2. Technology  Development -DOCRO shall develop purified ebaf antigens (native
and recombinant  protein and various peptides,  for all four known forms of ebaf
protein  expressed in human tissue (precursor ebaf protein having an approximate
molecular weight (including  native  glycosylation) of 42 kDa, and three clipped
forms of this precursor having  approximate  molecular weights (including native
glycosylation)  of 34 kDa,  26 kDa,  and 14 kDa) and then to raise a variety  of
monoclonal  antibodies  and polyclonal  antibodies to these various  antigens to
determine  if any ebaf  protein is  overexpressed  in the tissue,  blood,  other
fluids, and other specimen matrices from humans diagnosed with colorectal cancer
when compared to similar  specimens from apparently  healthy,  normal humans and
from  a  variety  of  humans   diagnosed  with  other   malignant   diseases  or
non-malignant diseases. Further, if an ebaf protein is determined by DOCRO to be
overexpressed  in  malignant  disease  and  not  in  non-malignant   disease  or
apparently  healthy  normals and LEXON  agrees,  DOCRO  shall  develop an enzyme
immunoassay  for such ebaf  protein to confirm the results in the blood or other
fluid specimen  matrix of a  statistically  significant  number (maximum of 400)
patients.

1.3. Analysis and Reports - DOCRO shall provide to LEXON an analysis and written
report of the work performed with recommendations for the next steps to be taken
by DOCRO  conducted in Section  1.1. and Section 1.2. on a bi-weekly  basis from
the inception of the project.  LEXON must provide written  notification to DOCRO
within  forty-eight  (48) hours of the  issuance of the report if LEXON  desires
DOCRO not to perform the work that DOCRO  recommends in the report.  DOCRO shall
provide to LEXON a written report  summarizing  DOCRO's  findings and activities
upon DOCRO's  completion of the technology  assessment portion of this Agreement
and upon termination of this Agreement.

1.4. The parties agree that DOCRO shall  provide  LEXON with its services  under
this  Agreement on a  non-exclusive  basis.  Subject to the  limitations of this
Agreement,  DOCRO and LEXON  may  provide  or  obtain  consulting  and  advisory
services to or from any third party.

1.5.  Pursuant  to the  terms  of this  Agreement,  DOCRO  shall  commence  work
immediately upon receipt of a fully executed  original of this Agreement and the
initial moneys set forth herein.

2.0   Term

2.1. The term of this  Agreement  shall  commence on 8 August  2000,  and shall
continue for a duration of one (1) year,  but after  DOCRO's  completion  of the
technology assessment portion of

                                   --3 of 14--

<PAGE>

this  Agreement  may be  terminated  at will by LEXON  giving  thirty  (30) days
written  notice to the other.  In the event of such  termination,  LEXON's  sole
obligation  to DOCRO shall be to pay DOCRO any fees and  expenses  for  services
either  (i)  rendered  by the date of  termination  or (ii) at  least  partially
rendered  and  committed  with  respect to any case report from an  investigator
working for DOCRO, such fees and expenses to be subtracted from the down payment
made by LEXON pursuant to Section 3.3. hereof.  The balance shall be returned to
LEXON.  In no event shall the amount due be greater than the amount set forth in
Section 3.

2.2. The confidentiality  provision of Section 4.0 of this Agreement shall be in
force for a period of three (3) years from the effective date of this Agreement.

3.0   Compensation & Reimbursement

3.1. DOCRO shall be compensated by LEXON  according to the terms of the attached
schedule (see  Attachment A. - Estimated Fees,  Milestone and Payment  Schedule)
and this Section 3.0 for the conduct of the technology assessment and technology
development professional services rendered by DOCRO under the provisions of this
Agreement.

3.2.  DOCRO  shall be  compensated  by LEXON for the  conduct of the  technology
assessment  and  technology  development  professional  services in total of one
million,  four hundred,  ninety-five  thousand dollars (US  $1,495,000.00).  The
first three (3) fully creditable and  non-refundable  payments to DOCRO totaling
five  hundred,  fifty  thousand  dollars (US  $550,000.00)  as described in this
section of the  Agreement and in any  attachment  to this  Agreement are made to
DOCRO for the conduct of the technology  assessment  portion of this  Agreement.
The first payment to DOCRO shall be a fully creditable,  non-refundable  advance
payment of one hundred thousand dollars (US $100,000.00)  upon execution of this
Agreement.   The  second   payment  to  DOCRO  shall  be  a  fully   creditable,
non-refundable  payment of two hundred,  fifty thousand dollars (US $250,000.00)
thirty (30) days after the date of execution of this contract. The third payment
to DOCRO  shall be a fully  creditable,  non-refundable  payment of two  hundred
thousand  dollars (US  $200,000.00)  sixty (60) days after the execution date of
this  Agreement.  The  basis  for these  amounts  and the  dates for  additional
payments to be made by LEXON to DOCRO are set forth in Attachment A. - Estimated
Fees,  Milestone  and  Payment  Schedule.  Such  payments  shall be made by wire
transfer to DOCRO's bank  account:  People's  Bank of  Connecticut,  Bridgeport,
Connecticut - Bank Routing Number  221172186,  Account Number  014-7006302.  The
aggregate  amount of the three advance  payments,  five hundred,  fifty thousand
dollars (US $550,000.00) shall be subtracted from the total payment due to DOCRO
hereunder.

3.3.  DOCRO  shall  bill  LEXON  for the  remaining  balance  of  nine  hundred,
forty-five  thousand  dollars  (US  $945,000.00)  plus any  additional  expenses
approved by LEXON and incurred as described in Attachment  A. - Estimated  Fees,
Milestone and Payment  Schedule for services  rendered on this contract shall be
billed to LEXON  according to Attachment A., such monies to be used by DOCRO for
the assay development portion of this Agreement.  LEXON shall reimburse DOCRO on
a net  fifteen  (15) day basis,  time  commencing  from  submission  to LEXON of
invoice and statement of work completed or expenses incurred.  If timely payment
for invoiced

                                   --4 of 14--

<PAGE>

fees is not made,  in  addition  to other  remedies,  DOCRO may impose and LEXON
shall pay, a late payment charge equal to one and one-half percent (1.5%) of the
overdue amount each month.

3.4.  DOCRO will notify  LEXON in writing  within five (5) working days from the
effective  date if the estimated  fees and expenses for this project  exceed one
million,  four hundred,  ninety-five  thousand dollars (US  $1,495,000.00)  (Fee
Cap),  including expenses described in Attachment A. - Estimated Fees, Milestone
and Payment Schedule, but not including additional expenses, in which case LEXON
may  terminate  the  Agreement.  DOCRO  shall  provide  LEXON a written  Project
Description & Estimate  (PDE)  describing  the new aspects or tasks  required to
complete  the  project.  The Fee Cap  shall  not  include  any fees or  expenses
applicable  to any  meeting  with any person or group other than  meetings  with
LEXON or with Dr. S.  Tabibzadeh to review work performed and planned related to
the technology assessment and development of the ebaf tumor marker technology.

3.5.  DOCRO shall not  initiate  any work the cost of which shall exceed the Fee
Cap prior to obtaining  LEXON's written  approval of a PDE. A PDE shall describe
the aspects of the project to be performed by DOCRO,  including a description of
the specific  personnel and other  resources  needed to perform the new tasks of
the project,  the time or schedule needed to complete such tasks, and a proposed
schedule  for project  related  payments.  The Fee Cap shall be increased by the
amount of any approved PDE.

3.6.  DOCRO  shall  ensure  that all charges  are  allocated  accurately  to the
activity or project for which such charges were  incurred,  and are supported by
documents.  The nature and purpose of all invoiced  items shall be identified in
the supporting documents.

3.7. DOCRO shall be paid for reasonable and necessary business expenses that are
incurred by DOCRO in the course of performing the  obligations of this Agreement
as described  in this  Agreement.  Such costs may include,  (but are not limited
to), the  following:  computer  research;  laboratory  expenses;  long  distance
telephone and telefacsimile charges;  postage, printing and courier charges; and
travel  expenses,  (including  the cost of  transportation,  meals and lodging).
LEXON shall  compensate  DOCRO fully for all travel and living expenses that are
not  described in  Attachment  A. but that either are agreed to by LEXON and are
incurred  for site visits to the premises of LEXON,  any clinical  investigator,
any laboratory investigator,  or any other location that may be requested or are
required  in order  for  DOCRO to  fulfill  its  obligations  described  in this
Agreement.

3.8. The cost to prepare any reagents,  materials,  or products by a third party
on  behalf of DOCRO and  LEXON  shall be  passed  on to LEXON  with an  eighteen
percent (18%) additional mark-up by DOCRO.  However,  any equipment,  materials,
consumables,  or non-ebaf  specific  reagent  paid for by LEXON shall become the
property of DOCRO upon the termination of this AGREEMENT.

                                   --5 of 14--

<PAGE>

4.0 Confidential & Proprietary Information

4.1.  DOCRO and LEXON hereby agree with respect to  Confidential  &  Proprietary
Information:   (1)  to  maintain  the  confidentiality  of  any  Confidential  &
Proprietary Information disclosed; (2) not to make any disclosure of proprietary
or confidential  information to any third party;  (3) not to use  Confidential &
Proprietary  Information except for the Purposes contemplated in this Agreement,
unless such further use is  specifically  authorized in writing by the party who
has  title  to the  information;  (4) to  protect  the  other's  Confidential  &
Proprietary  Information  whether in storage or in use,  with the same degree of
care as is exercised  to protect its own against  public  disclosure  (but in no
case  with  any less  degree  than  reasonable  care);  and (5) not to  disclose
Confidential  & Proprietary  Information  to any personnel  other than those for
whom  such  knowledge  is  essential  for  the  purposes  contemplated  in  this
Agreement,  and such  disclosure to them shall be made only under  conditions of
strict confidentiality.

4.2.  The  obligations  in this  Article  shall  not  apply  to  Confidential  &
Proprietary   Information   that  a  party  can  show  by  previously   existing
documentation:  (a) is in the public domain on the date of this  Agreement;  (b)
comes  into  the  public  domain  other  than  through  that  party's  fault  or
negligence;  (c) is  obtained  lawfully  from a third  party with full rights of
disclosure;  (d) was known  already  to that party at the date of receipt of the
information pursuant to this Agreement;  (e) becomes known independently to that
party without making use of any of the other party's  Confidential & Proprietary
information.

4.3. If this Agreement  expires or is terminated,  then a receiving  party shall
promptly return all  Confidential & Proprietary  Information,  together with all
copies thereof, except for the retention of one copy for archival purposes. Upon
a written request,  the parties shall respectively provide an accounting for the
disposition   of  all  such   documents  or   specimens,   including  a  written
certification  attesting  to return of all such  confidential  information.  The
parties shall return such items regardless of any claims against one another.

4.4.  No party  shall  make any  press  release  or  other  public  announcement
concerning  the terms or  execution  of this  Agreement  without  prior  written
consent of the other parties.

4.5. If a disclosure of  Confidential  & Proprietary  Information  prohibited by
this Agreement is specifically required by law or by court order, any party will
notify the other parties of such required disclosure and, if so requested,  will
execute all necessary documents and provide all reasonable  assistance necessary
to defend the other  party's  lawful right to prevent or limit such  disclosure.
The notifying party shall be entitled  reasonable  compensation for assisting in
such a defense.

5.0 Warranties & Certifications

5.1. DOCRO  warrants  that it shall  make  its best  efforts  to  evaluate  and
demonstrate  that the ebaf  technology  performs  technically  and clinically as
claimed by LEXON and by Dr. S.  Tabibzadeh,  North  Shore  University  Hospital,
North Shore, New York. However, DOCRO does

                                   --6 of 14--

<PAGE>

not  guarantee  that the  current  ebaf  reagents  or  assay  as run in  DOCRO's
laboratory  will meet or exceed the  performance  claims asserted by LEXON or by
Dr. S. Tabibzadeh.

5.2.  DOCRO does not guarantee  that the ebaf reagents and assay to be developed
by DOCRO  under the terms of this  Agreement  shall meet or exceed the claims of
LEXON nor does DOCRO  guarantee  that the  developed  assay  provide  sufficient
technical  or  clinical  performance  characteristics  nor  sufficient  clinical
sensitivity  and  specificity  to  warrant   additional  assay   development  or
subsequent  clinical trials,  including any trial intended for submission to FDA
for  LEXON to gain  approval  to market an ebaf  assay in the  United  States of
America.

5.3. DOCRO certifies that all of its employees, agents and contractors are bound
by the provisions of this  Agreement,  that it has obtained  written  agreements
from such  employees  and agents  that are  consistent  with the  provisions  of
Section 4.0 of this Agreement,  and that it will obtain written  agreements from
employees,  agents and contractors who in the future will become associated with
the project contemplated in this Agreement.

5.4.  DOCRO  represents  and certifies that it and its employees and agents have
all appropriate expertise, training, certifications, immunizations and equipment
to safely and lawfully  handle any materials,  perform any laboratory  tests, or
enter into work  areas  which may be  necessary  for work  performed  under this
Agreement.

5.5. LEXON certifies that all of its employees, agents and contractors are bound
by the provisions of this  Agreement,  that it has obtained  written  agreements
from such  employees  and agents  that are  consistent  with the  provisions  of
Section 4.0 of this Agreement,  and that it will obtain written  agreements from
employees,  agents and contractors who in the future will become associated with
the project contemplated in this Agreement.

5.6. LEXON warrants that no danger, hazard, or the like is known with respect to
its PRODUCTS,  other than those dangers known to be associated  with  infectious
blood samples.

5.7.  LEXON  and  DOCRO  warrant  that the  signatories  to this  Agreement  are
authorized to execute this Agreement on behalf of the respective parties.

6.0   Modification of Agreement

6.1. No waiver or modification of this Agreement shall be valid, nor shall it be
offered or received in evidence in any  proceeding,  arbitration  or  litigation
between the parties  arising  out of or related to this  Agreement,  unless such
waiver or  modification  is in writing signed by authorized  representatives  of
both parties,  particularly pointing out any provisions to be added, deleted, or
modified.

6.2. Unless  expressly  approved by the waiving party in accordance with Section
6.1.,  the failure of either party to enforce any  provision  of this  Agreement
shall not be  construed  as a waiver or  limitation  of that  party's  rights to
subsequently enforce and compel strict compliance with every

                                   --7 of 14--

<PAGE>

provision of the  Agreement.  No waiver  (express or implied) by either party of
any  breach  of this  Agreement  shall  constitute  a  waiver  of any  other  or
subsequent breach.

7.0 Assignment

This Agreement  shall be binding on and inure to the benefit of each party,  its
successors or assigns.  No assignment  shall be made by either party without the
express  written  consent of the other  party  except that LEXON may assign this
agreement to a purchaser of substantially all of the assets of LEXON.

8.0 Independent Contractor Status

8.1. It is expressly  stipulated,  agreed and understood  among the parties that
the business  relationship  between DOCRO and LEXON shall be that of independent
contractors,  and does not  constitute a partnership,  joint venture,  agency or
contract of employment.

8.2. No party shall have the authority to make any  statements,  representations
or  commitments  of any kind, or to take any action that shall be binding on the
other,  except as provided for herein or authorized in writing by the parties to
be bound.

8.3.  DOCRO shall be responsible  solely for provision of personnel,  equipment,
and  supplies,  and,  subject  to the terms of this  Agreement,  for  payment of
DOCRO's costs, suppliers,  employees and contractors. In no case shall any party
have the authority,  or represent  themselves as having the  authority,  to bind
legally any other in contract, debt or otherwise.

9.0   Notice

9.1. Any notice  required under this  Agreement  shall be deemed given only upon
receipt of any letter or  instrument  sent by  certified  mail,  return  receipt
requested,  postage prepaid by the sender,  by overnight  courier or by personal
delivery,  unless prior notice is tenured by the sender that a signed  telefaxed
response  followed  by  confirmation  by mail  will  satisfy  the  terms of this
provision.

If to DOCRO:                                   If to LEXON:
------------                                   ------------
Mr. Thomas F. Soriano                          Dr. Thomas R. Coughlin, Jr.
President and Chief Executive Officer          Medical Director
DIAGNOSTIC ONCOLOGY CRO, Inc.                  Lexon, Inc.
73 Cogwheel Lane                               8908 South Yale Avenue, Suite 409
Seymour, CT  06483                             Tulsa, OK  74137-3545

                                   --8 of 14--

<PAGE>

9.2.  From  time to time  either  party,  by  written  notice  to the  other  in
accordance  with this Section  11.0,  may  designate  different  or  alternative
addresses or manners of delivery that shall become the effective or  alternative
addresses, or manner of delivery, for such party or project as so designated.

10.0   Entire Understanding

This  Agreement  contains the complete  understanding  between the parties as to
conducting  the technology  assessment  and  technology  development of the ebaf
tumor  marker  technology,  but  shall not as of the date of  execution  of this
Agreement,  supersede the agreement  between the parties dated 04 April 2000 and
its extension dated 18 April 2000.

11.0   Severability

The terms of this Agreement are severable. If any term of this Agreement is held
invalid or unenforceable, the valid and enforceable portion of such term and the
remaining provisions of this Agreement will remain in full force and effect. The
remaining  contract  shall be  interpreted  consistently  with the intent of the
parties with respect to the entire Agreement when the contract was executed.

12.0 Dispute Resolution

12.1.  The  parties  agree  that they will use their  best  efforts  to  resolve
amicably  any  dispute  arising  out  of or  relating  to  this  Agreement.  Any
controversy,  claim or dispute  that cannot be so  resolved  shall be settled by
final  binding  arbitration  in  accordance  with  the  rules  of  the  American
Arbitration  Association  and judgment upon the award rendered by the arbitrator
or arbitrators may be entered in any court having jurisdiction thereof. Any such
arbitration  shall be conducted in  Connecticut.  Within one (1) month after the
commencement  of the  arbitration,  each party shall select one person to act as
arbitrator,  and the two arbitrators so selected shall select a third arbitrator
within one (1) month of their  appointment.  The  Arbitration  Period  shall not
exceed three (3) months. Each party shall bear its own costs and expenses and an
equal share of the arbitrator's expenses and administrative fees of arbitration.

12.2.  This Agreement  shall be governed by and construed in accordance with the
laws of the State of Connecticut, without consideration of choice of law.

13.0.  Headings

The headings  contained in this  Agreement are only for the  convenience  of the
parties and are not to be construed as a  substantive  provision and will not in
any manner affect the interpretation of this Agreement.

                                   --9 of 14--

<PAGE>

The parties execute this Agreement in accordance with all of the above terms and
conditions.

For Lexon, Inc.:

By: /s/ THOMAS COUGHLIN                     Date: August 2, 2000
    ----------------------------                  ---------------------
      Signature

      Thomas R. Coughlin, Jr., M.D.
      Medical Director

For DIAGNOSTIC ONCOLOGY CRO, Inc.:

By: /s/ THOMAS F. SORIANO                   Date: July 17, 2000
    ----------------------------                  ---------------------
      Signature

      Thomas F. Soriano
      President and Chief Executive Officer

                                  --10 of 14--

<PAGE>

ATTACHMENT A. - Estimated Fees,  Milestones and Payment
Schedule - Lexon, Inc. - ebaf Technology Assessment and
Development Project

Work to be Performed by DOCRO

1.   DOCRO shall assess the technical and clinical  performance  characteristics
     of the currently  existing  ebaf  reagents  (raw,  partially  purified,  or
     purified ebaf proteins (native or recombinant) or peptides and any antibody
     thereto)  provided to DOCRO by Dr. S.  Tabibzadeh,  North Shore  University
     Hospital,  North Shore,  New York or LEXON to determine if any ebaf protein
     is overexpressed  in humans diagnosed with colorectal  cancer when compared
     to humans  diagnosed  with a disease  other  than  colorectal  cancer or to
     apparently healthy, normal humans.

2.   If one or more ebaf proteins meets the  specifications in 1., above,  DOCRO
     shall develop  and/or refine ebaf antibody and antigen  reagents with which
     DOCRO shall develop and then characterize a microtiter  plate-based  enzyme
     immunoassay to determine the amount of that  particular ebaf protein in the
     blood or other fluid matrix of human subjects.

3.   DOCRO shall  contract  with,  manage,  oversee,  and  coordinate  all other
     contractors and  subcontractors who provide any material prepared under the
     terms of this Agreement.

4.   DOCRO  shall  provide  to LEXON on a  bi-weekly  basis  written  reports of
     DOCRO's  progress  and  recommendations  for the next segment of work to be
     performed.   LEXON  must  provide  written  notification  to  DOCRO  within
     forty-eight (48) hours of the issuance of the report if LEXON desires DOCRO
     not to perform the work that DOCRO recommends in the report.

5.   DOCRO shall provide to LEXON a written report summarizing  DOCRO's findings
     and activities upon DOCRO's completion of the technology assessment portion
     of this Agreement and upon termination of this Agreement.

                                  --11 of 14--

<PAGE>

Blank Page

                                  --12 of 14--

<PAGE>

<TABLE>
<CAPTION>

A.  ESTIMATED Milestone and Payment Schedule:

<S>                                                                                 <C>                <C>
                                                                                   ESTIMATED        MILESTONE Payment Made by Lexon
Milestone                                                                    Completion Date        and Received by DOCRO
---------                                                                    ---------------        ---------------------

1.  LEXON and DOCRO EXECUTE CONTRACT/First Payment                              28 July 2000        US $  100,000.00

2.  Project Meeting with Dr. Tabibzadeh to Launch Project                        11 Aug 2000

3.  Transfer of portions of ebaf peptides, proteins, and antibodies              11 Aug 2000
    From Dr. Tabibzadeh's laboratory to DOCRO's laboratory

4.  Laboratory Work at DOCRO commences and continues through project             14 Aug 2000
         a.  Adds second bench staff personnel                                   28 Aug 2000        US $  250,000.00
         b.  Interview and selection of contractor(s) for development and        28 Aug 2000
             Production of peptides and polyclonal and monoclonal antibodies
         c.  Initiate purification of native ebaf                                11 Sep 2000
         d.  Initiate expression cloning of ebaf                                 11 Sep 2000
         e.  Acquire fresh frozen tumor and clinical sample sets from                ONGOING
              colorectal cancer patients
         f.  Characterize reagents produced by Dr. Tabibzadeh                   28 Sept 2000        US $  200,000.00
              - chromatography, electrophoresis/blotting, etc.
         g.  Testing clinical sample sets (cancer, normal, benign)                   ONGOING

5.  DOCRO and contractor(s) prepare peptides for Mab and Pab contractor(s)       16 Sep 2000

6.  DOCRO completes selection and purification of native/recombinant             13 Nov 2000
    ebaf proteins, ships sufficient quantities to Mab and Pab contractor(s)

7.  DOCRO receives first bleeds of Pab's to peptides; purify/test                20 Nov 2000

</TABLE>

                                  --13 od 14--

<PAGE>

<TABLE>
<CAPTION>

      <S>                                                                            <C>                <C>    <C>

8.  DOCRO receives second bleeds of Pab's to peptides; purify/test               19 Nov 2000        US $  400,000.00
    DOCRO receives first Mab's to peptides; purify/test

9. DOCRO receives first bleeds of Pab's to proteins; purify/test                 11 Jan 2001        US $  400,000.00
    DOCRO receives third bleeds of Pabs to peptides; purify/test

10. DOCRO receives second bleeds of Pab's to proteins; purify/test               06 Mar 2001
    DOCRO receives first Mab's to proteins; purify/test

11. DOCRO optimizes EIA sandwich assay for the form of ebaf upregulated          11 May 2001
    in colon cancer and test clinical samples

12. DOCRO issues written report of findings and recommendations to LEXON         31 May 2001        US $  145,000.00

13  LEXON makes GO/NO GO decision                                                15 Jun 2001
------------------------------------------------------------------------------------------------------------------------

                                                              TOTAL                10 MONTHS        US $1,495,000.00

</TABLE>

Comments:

Item 5. - Analysis of Tissue  Distribution  Data is critical  component  to this
project.

Item 7. - This  assumes the  concentration  of ebaf is greater than 50 microgram
per gram of colon cancer tissue. If this minimum  concentration is not achieved,
this milestone will depend solely upon  recombinant ebaf protein produced by/for
Dr. S. Tabibzadeh.

Item  12.  - This  milestone  will  be  completed,  most  likely  using  peptide
polyclonal antibodies.

                                  --14 of 14--EMPLOYMENT AGREEMENT

This Employment Agreement, effective as of January 3, 2001 (the "Agreement"), is
entered into by and between LEXON,INC., an Oklahoma corporation (the "Company"),
the principal offices of which are located at 8908 South Yale Avenue, Suite 409,
Tulsa, Oklahoma,  74137, and GIFFORD M. MABIE ("Mabie"). In consideration of the
mutual covenants and conditions  contained in this Agreement,  the parties agree
to the following:

                                    ARTICLE 1
                             DUTIES AND COMPENSATION

1.01.    Term of Employment  and Duties.  The Company and Mabie agree that for
         the period commencing on January 3, 2001, and terminating on January 3,
         2002 (the "Termination Date"), the Company shall employ Mabie and Mabie
         shall  perform  duties  ("duties")  for the Company as Chief  Executive
         Officer  and  President  of the  Company as set forth in the  Company's
         Bylaws  and  shall  report to the  Company's  Board of  Directors  (the
         "Board").

1.02.    Commitment to the Company.  During the term of this Agreement,  Mabie
         shall devote such working time,  attention and energies to the business
         of the Company,  as is necessary or appropriate  for the performance of
         his duties as Chief  Executive  Officer and  President  of the Company.
         However,  this  commitment  shall not be construed as preventing  Mabie
         from  participating  in  other  businesses  or from  investing  Mabie's
         personal  assets in such form or manner as may  require  occasional  or
         incidental  time on the part of Mabie in the  management,  conservation
         and protection of such  investments and provided that such  investments
         or business  cannot be  construed as being  competitive  or in conflict
         with the business of the Company.

1.03.    Renewal of Term.  Upon each  Termination  Date this  Agreement  shall
         renew and continue in effect for an  additional  two-year  period,  and
         each successive  Termination Date shall thereafter be designated as the
         "Termination Date" for all purposes under this Agreement.

1.04.    (a)  Compensation.  Mabie shall receive a salary of  $100,000.00  per
         year, payable in 24 semi-monthly  installments.  Each January the Board
         shall review  Mabie's salary and shall make such increases in salary as
         it  considers  appropriate.  Mabie's  salary  during  the  term of this
         Agreement shall never be less than  $100,000.00 per year.  Effective at
         the beginning of each calendar year Mabie shall be entitled to at least
         an increase in salary that is equal to the  percentage  increase in the
         Consumer Price Index during the previous calendar year.

         (b) Bonus. During the term of this Agreement Mabie shall be entitled to
         participate  in all  executive  bonuses  as  the  Board,  in  its  sole
         discretion, shall determine.

         (c) Fringe  Benefits.  During the term of this  Agreement  the  Company
         shall provide to Mabie each of the  following:  (i) all  reasonable and
         customary executive "fringe benefits,"  including,  but not limited to,
         participation in pension plans,  profit-sharing  plans,  employee stock
         ownership plans,  stock option plans (whether  statutory or not), stock
         appreciation   rights   plans,   hospitalization   insurance,   medical
         insurance, dental insurance,  disability insurance, life insurance, and
         such other  benefits that are granted to or provided for executives now
         in the employ of the Company or that may be granted to or provided  for
         them during the term of Mabie's  employment  under this Agreement;  and
         (ii) paid vacation and sick leave, as determined by the Board.

         (d)  Reimbursement  of Expenses.  (i) During the term of this Agreement
         the Company  shall pay directly or reimburse  Mabie for all  reasonable
         and necessary travel, entertainment, or other

                                       1
<PAGE>
          related  expenses  incurred  by him in  carrying  on  his  duties  and
          responsibilities under this Agreement.  In addition, the Company shall
          furnish Mabie with a cellular  telephone and suitable office space and
          facilities for the performance of his duties.  (ii) During the term of
          this  Agreement the Company shall pay for Mabie's  membership  dues in
          professional  organizations  and  for  any  seminars  and  conferences
          related to Company business.

1.05.    (a) Indemnification.  Mabie shall be indemnified by the Company for all
         legal  expenses and all  liabilities  incurred in  connection  with any
         proceeding  involving  him by reason  of his  being or  having  been an
         officer,  director,  employee,  or agent of the  Company to the fullest
         extent permitted by the laws of the State of Oklahoma.

         (b)  Payment of  Expenses.  In the event of any action,  proceeding  or
         claim  against  Mabie  arising out of his serving or having served in a
         capacity  specified  in  Section  1.01  above,  which in  Mabie's  sole
         judgment  requires him to retain  counsel (such choice of counsel to be
         made by Mabie  with the prior  consent  of the  Company,  which may not
         unreasonably  withhold its  consent) or  otherwise  expend his personal
         funds for his defense in  connection  therewith,  the Company shall pay
         for or reimburse Mabie for all reasonable  attorney's fees and expenses
         and other costs  associated with Mabie's defense of such action as such
         fees and costs are incurred.

                                   ARTICLE II
                            TERMINATION OF EMPLOYMENT

2.01.    Termination  Procedure.  Either party to this  Agreement  may terminate
         Mabie's  employment  under this  Agreement  by giving  the other  party
         written notice of the intent to terminate at least thirty days prior to
         the  proposed  termination  date except as set out in section  2.02.  A
         decision  by the Company to  terminate  Mabie's  employment  under this
         Agreement shall require an affirmative vote of more than 66-2/3% of the
         Board except as set out in Section 2.02.

2.02.    Death.  This Agreement shall terminate on the date of Mabie's death. If
         this Agreement is terminated as a result of Mabie's death,  the Company
         shall pay to Mabie's estate,  not later than the 30th day following his
         death,  a lump sum severance  payment  consisting of (1) Mabie's salary
         and accrued salary through the date of his death, (2) all amounts Mabie
         would have been entitled to upon  termination of his  employment  under
         the Company's employee benefit plans and (3) a pro rata amount of bonus
         Mabie was eligible to receive under any Company bonus plan.

2.03.     Disability.  The  Company  shall  have  the  right to  terminate  this
          Agreement  if Mabie incurs a permanent  disability  during the term of
          his employment  under this Agreement.  For purposes of this Agreement,
          "Permanent  Disability"  shall mean  inability of Mabie to perform the
          services required hereunder due to physical or mental disability which
          continues  for  either  (i) a total of 180  working  days  during  any
          12-month  period or (ii) 150  consecutive  working  days. In the event
          that either party disputes  whether Mabie has a permanent  disability,
          such dispute shall be submitted to a physician mutually agreed upon by
          Mabie or his legal guardian and the Company. If the parties are unable
          to agree on a mutually  satisfactory  physician,  each shall  select a
          reputable  physician,  who,  together,  shall  in turn  select a third
          physician  whose  determination  of Mabie's ability to perform his job
          duties shall be  conclusive  and binding to the  parties.  Evidence of
          such disability shall be conclusive  notwithstanding that a disability
          policy or clause in an insurance policy covering Mabie shall contain a
          different definition of "permanent  disability." If Mabie's employment
          under this  Agreement is  terminated  by the Company  because he has a
          permanent disability,  the Company shall pay Mabie, not later than the
          30th day  following  the  date of  termination,  a lump sum  severance
          payment  consisting  of (1)  Mabie's  salary  through  the date of

                                       2
<PAGE>

          his termination, (2) all amounts Mabie is entitled to upon termination
          of employment under the Company's  employee benefit plans, (3) Mabie's
          undiscounted  salary through the Termination Date, or if greater for a
          period of 24 months, and (4) a pro rata amount of bonus he is eligible
          to receive under any Company bonus program.

2.04.     Termination  With Cause. The Company shall have the right to terminate
          this Agreement for cause. For purposes of this Agreement,  "for cause"
          shall  exclusively be defined to mean (a) conviction of a felony which
          is  materially   detrimental  to  the  Company,  (b)  proof  beyond  a
          reasonable doubt of the gross  negligence or willful  misconduct which
          is  materially  detrimental  to the  Company,  or (c)  proof  beyond a
          reasonable  doubt of a breach of a fiduciary  duty which is materially
          detrimental  to  the  Company.   If  the  Company  terminates  Mabie's
          employment "for cause" the Company shall pay Mabie, not later than the
          30th day  following  the  date of  termination,  a lump sum  severance
          payment  consisting of (1) Mabie's  salary and accrued  salary through
          the date of his  termination  and (2) all amounts Mabie is entitled to
          upon termination of employment under the Company's  employee  benefits
          plans.

2.05.    Termination Without Cause. If the Company terminates Mabie's employment
         for any reason  other than for cause as that term is defined in section
         2.04,  the  Company  shall  pay  Mabie,  not  later  than  the 30th day
         following  the  date  of  termination,  a lump  sum  severance  payment
         consisting of (1) Mabie's salary and accrued salary through the date of
         his termination,  (2) all amounts Mabie is entitled to upon termination
         of employment under the Company's  employee benefits plans, (3) Mabie's
         undiscounted  salary through the Termination  Date, or if greater for a
         period of 24 months,  and (4) a pro rata amount of bonus he is eligible
         to receive under any Company bonus program.

2.06.    Resignation.  If Mabie resigns from his employment under this Agreement
         other  than for a reason of change of  control  as  defined  in section
         2.07,  the  Company  shall  pay  Mabie,  not  later  than  the 30th day
         following the effective date of his  resignation,  a lump sum severance
         payment consisting of (1) Mabie's salary and accrued salary through the
         date of his  termination,  (2) all  amounts  Mabie is  entitled to upon
         termination of employment  under the Company's  employee benefit plans,
         (3)  Mabie's  undiscounted  salary  for a period  of 90 days  after his
         resignation  and (4) a pro  rata  amount  of bonus  he is  eligible  to
         receive under any Company bonus program.

2.07.     Change of  Control.  Mabie  shall  have the  right to resign  from his
          employment  under this Agreement if there is a change of control.  For
          purposes of this Agreement a Change of Control shall be deemed to have
          occurred  if any of the  following  occur:  (i) at any time during any
          period of 12 consecutive  months, at least a majority of the directors
          serving on the Board ceases to consist of individuals  who have served
          continuously  on such  Board  since  the  beginning  of such 12  month
          period,  unless the  election  of  directors  during such  period,  or
          nomination  for  election  by the  shareholders  of the  Company,  was
          approved by a vote of at least two-thirds of the members of such Board
          at such time still in office and who shall have served continuously on
          such Board since the  beginning of such  12-month  period by reason of
          death or disability; or (ii) a merger or consolidation occurs to which
          the Company is a party unless  following such merger or  consolidation
          (A) more than 50% of the then  outstanding  shares  of voting  capital
          stock of the corporation  surviving such merger or resulting from such
          consolidation is then beneficially owned,  directly or indirectly,  by
          all or substantially  all of the individuals and entities who were the
          beneficial  owners  of the  outstanding  voting  capital  stock of the
          Company   immediately   prior  to  such  merger  or  consolidation  in
          substantially  the same  proportions as their  ownership,  immediately
          prior to such  merger  or  consolidation,  of the  outstanding  voting
          capital  stock  of the  Company,  and (B) at least a  majority  of the
          members of the Board  surviving  such  merger or  resulting  from such
          consolidation  were  members  of the Board  immediately  prior to such
          merger

                                       4

<PAGE>
          or consolidation;  or (iii) the sale of all, or substantially  all, of
          the  assets of the  Company;  or (iv) a person or entity who is not an
          owner of voting  capital  stock of the  Company as of the date of this
          Agreement  acquires  more than 50% of the voting  capital stock of the
          Company.  Notwithstanding the foregoing,  however, a Change of Control
          shall not be  deemed  to have  occurred  upon the  consummation  of an
          Initial Public Offering of the capital stock of the Company.  If Mabie
          exercises his right to terminate his employment  following a Change of
          Control,  he shall receive,  not later than the 30th day following the
          date of termination,  a lump sum severance  payment  consisting of (1)
          Mabie's  salary through the date of his  termination,  (2) all amounts
          Mabie  is  entitled  to  upon  termination  of  employment  under  the
          Company's  employee  benefits plans, (3) Mabie's  undiscounted  salary
          through the Termination Date, or if greater for a period of 24 months,
          and (4) a pro rata amount of bonus he is eligible to receive under any
          Company bonus program.

2.08.     Mitigation.  Mabie shall have no obligation to mitigate any damages or
          payments made to him under Article II of this Agreement.

2.09.    Excess  Parachute  Payments.  In the event that  payment of the amounts
         this  Agreement  requires the Company to pay Mabie would cause Mabie to
         be the recipient of an excess parachute  payment (within the meaning of
         Section  280G(b) of the Internal  Revenue Code of 1986),  the amount of
         the payments to be made to Mabie  pursuant to this  Agreement  shall be
         reduced  to an amount  equal to one dollar  less than the  amount  that
         would cause the payments hereunder to be excess parachute payments. The
         manner in which such reduction  occurs,  including the items of payment
         and amounts thereof to be reduced,  shall be agreed to by Mabie and the
         Company.

                                   ARTICLE III
                    RESTRICTIONS DURING AND AFTER EMPLOYMENT

3.01.    Non-Compete.  During  Mabie's  employment  by the  Company  under  this
         Agreement  and for a  one-year  period  following  the  termination  of
         Mabie's  employment  by the  Company,  except  if such  termination  is
         pursuant to sections  2.05 or 2.07 of this  Agreement,  Mabie shall not
         work for or provide any services in any capacity to any  individual  or
         business entity that is in direct  competition with the business of the
         Company as it exists during Mabie's employment with the Company.

3.02.    Soliciting  Customers  Or Accounts  After  Termination  of  Employment.
         During the one-year  period  immediately  following the  termination of
         Mabie's  employment  with the Company,  except if such  termination  is
         pursuant to sections  2.05 or 2.07 of this  Agreement,  Mabie shall not
         either directly or indirectly:  (a) Make known to any person,  firm, or
         corporation the names and addresses of any of the customers or accounts
         of the Company;  or (b) Call on,  solicit,  or take away, or attempt to
         call on, solicit,  or take away any of the customers or accounts of the
         Company on whom Mabie called or with whom he became  acquainted  during
         his  employment  with the Company,  either for himself or for any other
         person, firm, or corporation.

3.03.    Company  Records  and  Documents.   All  Company-related   records  and
         documents are  considered to be the exclusive  property of the Company.
         Upon the  termination  of Mabie's  employment  by the  Company  for any
         reason,  he shall  promptly  return to the Company all such records and
         documents in his possession or under his control.  Mabie shall have the
         right to  retain  copies  of  Company  records  and  documents  that he
         believes  are  reasonably  necessary  for him to  retain  to be able to
         exercise  his  rights  under  the  Indemnification  Provisions  of this
         Agreement.

                                       4
<PAGE>
                                   ARTICLE IV
                                  MISCELLANEOUS

4.01.     Notice.  Any  notice  required  or  permitted  to be given  under this
          Agreement shall be sufficient if in writing and sent by certified mail
          by the Company to the residence of Mabie, or by Mabie to the Company's
          principal office.

4.02.     Further Assurances.  Each party agrees to perform any further acts and
          to execute and deliver any further  documents  that may be  reasonably
          necessary to carry out the provisions of this Agreement.

4.03.     Severability.  In the event that any of the  provisions,  or  portions
          thereof,  of this Agreement are held to be unenforceable or invalid by
          any court of competent  jurisdiction,  the validity and enforceability
          of the remaining provisions or portions thereof, shall not be affected
          thereby.

4.04.     Construction.  Whenever used herein, the singular number shall include
          the plural, and the plural number shall include the singular.

4.05.     Headings. The headings contained in this Agreement are for purposes of
          reference only and shall not limit or otherwise  affect the meaning of
          any of the provisions contained herein.

4.06.     Multiple  Counterparts.  This  Agreement  may be  executed in multiple
          counterparts,  each of which shall be deemed to be an original but all
          of which together shall constitute one and the same instrument.

4.07.     Governing  Law.  This  Agreement  has been  executed  in and  shall be
          governed by the laws of the State of Oklahoma.

4.08.    Inurement.  Subject to the restrictions  against transfer or assignment
         as herein  contained,  the provisions of this Agreement  shall inure to
         the  benefit of, and shall be binding on, the  assigns,  successors  in
         interest, personal representatives, estates, heirs and legatees of each
         of the parties hereto.

4.09.    Waivers.  No waiver of any  provision or  condition  of this  Agreement
         shall be valid unless executed in writing and signed by the party to be
         bound thereby, and then only to the extend specified in such waiver. No
         waiver  of any  provision  or  condition  of this  Agreement  shall  be
         construed  as a waiver  of any other  provision  or  condition  of this
         Agreement,  and no present waiver of any provision or condition of this
         Agreement  shall be construed as a future  waiver of such  provision or
         condition.

4.10.     Amendment.  This  Agreement may be amended only by a written  document
          signed by the  parties and  stating  that the  document is intended to
          amend this Agreement.

4.11.    Disputes. In any dispute or proceeding to construe this Agreement,  the
         parties  expressly  consent to the exclusive  jurisdiction of state and
         federal  courts  in Tulsa  County,  Oklahoma,  the  principal  place of
         business  for  Lexon.  The  prevailing  party in any suit  brought  to
         interpret  this  Agreement  shall be  entitled  to  recover  reasonable
         attorney's  fees and  expenses in addition to any other relief to which
         it is entitled.

                                       5
<PAGE>

4.12.    Payment  of  Mabie's   Attorney's  Fees  and  Expenses  in  Advance  in
         Connection  with this  Agreement.  If the Company brings a suit against
         Mabie in connection with this Agreement or if Mabie brings suit against
         the Company in connection  with this  Agreement,  the Company shall pay
         Mabie's  reasonable  attorney's  fees and  expenses as  incurred.  If a
         determination is made in a court of competent  jurisdiction in favor of
         the Company,  then the Company  shall be entitled to be  reimbursed  by
         Mabie  for his  attorney's  fees and  expenses  which  were paid by the
         Company.

4.13.     Execution. Each party to this Agreement hereby represents and warrants
          to the other  party  that such party has full  power and  capacity  to
          execute, deliver and perform this Agreement.

IN WITNESS  WHEREOF,  the parties to this Agreement have executed this Agreement
effective this 3rd day of January, 2001.

GIFFORD M. MABIE                        LEXON, INC.

/s/ GIFFORD M. MABIE                    /s/ GIFFORD M. MABIE
--------------------------------------  ----------------------------------------
Gifford M. Mabie, an Individual         By:  Gifford M. Mabie
                                        President and Chief Executive Officer

                                       6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00024-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00024-of-00352.parquet"}]]